Alchemab Therapeutics enters into collaboration with Lilly to discover, research and develop novel therapies for ALS
Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab’s antibody discovery platform.
Cambridge, UK, 9 January 2025 – Alchemab Therapeutics (Alchemab), a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces it has entered a collaboration with Lilly to discover novel therapeutic candidates to treat amyotrophic lateral sclerosis (ALS). Alchemab’s technology platform uses patient samples from individuals with unusually slow rates of disease progression to identify antibodies associated with resilience. Alchemab believes these antibodies, which are not found in disease progressors, could present therapeutic opportunities.
